Acacia Subsidiary Acquires 7 Medtech Patent Portfolios with over 150 Patents and Pending Applications
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jun 11, 2012-- Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary has acquired 7 medtech patent portfolios comprised of over 150 patents and pending applications relating to medical devices, biologics and diagnostic techniques.
"Acacia continues to increase the number of patent portfolios we control in the medical technology and life sciences sector," states Paul Ryan, CEO and President. "We are rapidly expanding our presence as a leader in patent licensing in the medical device, diagnostics and life sciences sectors." ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation's subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research Corporation's subsidiaries control over 200 patent portfolios, covering technologies used in a wide variety of industries.
Information about Acacia Research Corporation and its subsidiaries is available at www.acaciaresearchgroup.comand www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our ability to expand our presence in patent licensing in the medical device, diagnostics and life science sectors and our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the ability to successfully develop licensing programs and attract new business, rapid technological change in relevant markets, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
CONTACT: Acacia Research Corporation Rob Stewart Investor Relations Tel 949-480-8300 Fax 949-480-8301 or Media Contact: Lippert/Heilshorn & Associates Adam Handelsman Managing Director 212-201-6622 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES MEDICAL SUPPLIES SOURCE: Acacia Research Corporation Copyright Business Wire 2012 PUB: 06/11/2012 06:00 AM/DISC: 06/11/2012 06:00 AM http://www.businesswire.com/news/home/20120611005223/